{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-027837","form_type":"8-K","ticker":"CLNN","cik":"0001822791","company_name":"Clene Inc.","filed_at":"2026-08-14T12:35:24+00:00","discovered_at":"2026-08-14T12:40:00.428588+00:00","generated_at":"2026-08-14T12:40:09.916126+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Clene Q2 net loss $13.4M; NDA for CNM-Au8 in ALS expected early Q4 2026","bullets":["NDA for CNM-Au8 in ALS under accelerated approval expected early Q4 2026; FDA confirmed data may support submission.","Cash $9.7M at June 30 vs $5.2M at Dec 31; runway through late Q4 2026.","Net loss $13.4M ($1.08/share) vs $7.4M ($0.78) in Q2 2025; other expense $8.1M on warrant/derivative fair value.","R&D flat at $3.5M; G&A down to $1.9M from $2.4M.","Closed $7M offering; extended convertible debt maturities to Aug 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-027837","json":"https://secwatch.observer/filing/0001437749-26-027837.json","markdown":"https://secwatch.observer/filing/0001437749-26-027837.md","text":"https://secwatch.observer/filing/0001437749-26-027837.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822791/000143774926027837/0001437749-26-027837-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822791/000143774926027837/clnn20260524_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T12:40:09.916126+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}